Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2024 · 10-Q
Revenue$0.00$0.00derived— vs Q2 2023 Net Income-$8.21M-$8.21MN/M vs Q2 2023 EPS Diluted-$4.42-$4.42N/M vs Q2 2023 Operating Income-$4,496,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,706,000N/M ended Dec 31, 2023 · filed Feb 9, 2024 · 40 d after period end